Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dostarlimab-gxly + GSK5733584 |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dostarlimab-gxly | Jemperli | Dostarlimab|TSR-042 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Jemperli (dostarlimab-gxly) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 34313545). Jemperli (dostarlimab-gxly) is FDA approved for use in patients with recurrent or advanced endometrial cancer or solid tumors harboring mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have progressed on prior treatments, and in combination with Paraplatin (carboplatin) and Taxol (paclitaxel), followed by Jemperli (dostarlimab-gxly) monotherapy, in patients with primary advanced or recurrent endometrial cancer (FDA.gov). |
| GSK5733584 | GSK 5733584|GSK-5733584|HS-20089 | GSK5733584 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting VTCN1 (B7-H4) linked to a topoisomerase I inhibitor, which potentially induces apoptosis in VTCN1 (B7-H4)-expressing tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT188, NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06796907 | Phase Ib/II | GSK5733584 Bevacizumab + GSK5733584 Dostarlimab-gxly + GSK5733584 | A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | Recruiting | TUR | SWE | POL | NOR | NLD | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BEL | AUS | ARG | 3 |
| NCT01042379 | Phase II | GSK5733584 Zanidatamab Cemiplimab + VSV-hIFNbeta-NIS Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab ARX-788 Letrozole + Vepdegestrant Lasofoxifene Datopotamab deruxtecan + Durvalumab Abemaciclib + Vepdegestrant Dostarlimab-gxly + GSK5733584 Cemiplimab + Paclitaxel + Sarilumab Abemaciclib + Z-endoxifen HCl DAN-222 + Niraparib Datopotamab deruxtecan Vepdegestrant AZD2936 + Trastuzumab deruxtecan Z-endoxifen HCl | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY) | Recruiting | USA | 0 |
CKB BOOST